Research programme: long acting psychedelic analogues - Otsuka America Pharmaceutical
Alternative Names: Family 3 - next-generation psilocybin; MSP-3002Latest Information Update: 09 Jan 2024
At a glance
- Originator Mindset Pharma
- Developer Otsuka America Pharmaceutical
- Class Antipsychotics; Small molecules
- Mechanism of Action Serotonin 5-HT2A receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Neurological disorders; Psychiatric disorders
Most Recent Events
- 01 Jan 2024 Mindset Pharma has been acquired and merged into Otsuka America Pharmaceutical
- 10 Jun 2022 Mindset Pharma receives patent allowance for Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders in US
- 29 Dec 2021 Mindset Pharma files international patent application for Family 3 psychedelic compounds